27 C
Vientiane
Sunday, June 1, 2025
spot_img
Home Blog Page 363

OCI GLOBAL CONFIRMS EURO EQUIVALENT DETAILS FOR Q2 2025 EXTRAORDINARY DISTRIBUTION

AMSTERDAM, April 16, 2025 /PRNewswire/ — OCI Global (Euronext: OCI) (“OCI” or the “Company”) today confirms that further to its announcement to pay an extraordinary cash distribution of USD 4.74 per share (USD 1.0 billion in total) on or around 7 May 2025, the Euro equivalent amount for those shareholders that elect for payment in EUR instead of USD will be determined using the appropriate exchange rate on 6 May 2025. The Company will make a distribution in USD unless the relevant shareholder has opted for a distribution in EUR.

About OCI Global
Learn more about OCI at www.oci-global.com. You can also follow OCI on LinkedIn.

Deltek Appoints Dan Barnhardt as Chief Marketing Officer

Go-to-market leader will elevate Deltek’s global marketing efforts

HERNDON, Va., April 16, 2025 /PRNewswire/ — Deltek, the leading global provider of enterprise software and solutions for project-based businesses, today announced the appointment of Dan Barnhardt as Chief Marketing Officer (CMO). Dan will report to Natasha Engan, SVP and Chief Commercial Officer.

Dan Barnhardt joins Deltek as Chief Marketing Officer
Dan Barnhardt joins Deltek as Chief Marketing Officer

Barnhardt joins the company with a proven track record of driving brand transformation, scaling go-to-market strategies and strengthening market leadership in fast-paced environments.

Most recently, Barnhardt was Vice President of Corporate Marketing at Icertis, where he helped triple revenue by positioning the company as the leader in contract intelligence and built a modern demand engine. Prior to that, he held marketing leadership positions at Precisely and Infor, helping fuel expansion and defining new categories for the brands.

“Dan’s creative and strategic approach to marketing will be instrumental as we sharpen Deltek’s voice and modernize how we engage in the market,” said Bob Hughes, Deltek President and CEO. “Dan brings a passion for digital marketing and a track record of helping brands connect with customers in authentic and differentiated ways — a strength that will support our efforts across Deltek Project Nation.”

As CMO, Barnhardt will lead all aspects of Deltek’s global marketing organization, focusing on brand evolution, digital engagement, demand generation and customer advocacy.

“Deltek became a global leader trusted by 30,000 customers by distinguishing itself through a commitment to customer service and product excellence, and the opportunity to build on that strong foundation is incredibly exciting,” said Dan Barnhardt, Chief Marketing Officer, Deltek. “I’m looking forward to connecting with Deltek customers, partners, and team members alike as we accelerate growth for the next chapter of the company’s evolution.”

Barnhardt holds a Bachelor of Arts in Economics from Vanderbilt University.

About Deltek

Better software means better projects. Deltek is the leading global provider of enterprise software and information solutions for project-based businesses. More than 30,000 organizations and millions of users in over 80 countries around the world rely on Deltek for superior levels of project intelligence, management, and collaboration. Our industry-focused expertise powers project success by helping firms achieve performance that maximizes productivity and revenue. www.deltek.com

Deltek Contact
Deltek Media Relations Team
press@Deltek.com

 

Frost & Sullivan Recognizes Ontic with the 2025 Global Company of the Year Award for Revolutionizing Security Intelligence

Ontic’s unified platform empowers corporate security teams to manage threats, mitigate risks, and make businesses stronger.    

SAN ANTONIO, April 16, 2025 /PRNewswire/ — Frost & Sullivan recently researched the digital intelligence solutions industry and, based on its findings, recognizes Ontic with the 2025 Global Company of the Year Award. Ontic is redefining security intelligence with its always-on digital intelligence platform, empowering security teams with situational awareness, deep contextual analysis, and predictive threat detection.

Ontic’s Connected Intelligence platform transforms fragmented security operations into an integrated hub that enables proactive threat management. By centralizing critical data on principals, threats, and incidents, Ontic eliminates the blind spots that plague traditional security approaches and enables early threat detection. In today’s environment of expanded threats, sophisticated threat actors, and the critical importance of digital intelligence, Ontic provides security teams with the foundation they need to evolve from reactive responders to strategic business enablers. As an end-to-end technology solution, the platform integrates intelligence, investigative research, threat assessments, and incident and case management workflows with critical business systems, creating a continuous security intelligence cycle that anticipates threats before they materialize.

What sets Ontic apart is its ability to unify traditionally sold security functions while enhancing cross-functional collaboration across the enterprise. Advanced machine learning algorithms and robust open-source intelligence (OSINT) capabilities enable security teams to intercept threat signals, conduct comprehensive risk assessments, implement continuous monitoring, and coordinate responses—all within a single, user-friendly experience. Through intelligent automation and streamlined workflows, Ontic helps security teams achieve more with constrained resources, demonstrating measurable impact that positions security as a strategic partner to the business rather than a cost center. These groundbreaking features push the boundaries of digital intelligence solutions and position Ontic as one of the most influential players in the digital intelligence solutions industry.

“Rather than relying on more passive or reactive security processes and activities, modern security teams are striving to be more proactive in detecting security threats before they can impact critical business operations,” said Danielle VanZandt, research manager for Frost & Sullivan’s security business unit.

Ontic’s leadership in the digital intelligence market is driven by its strong commitment to innovation, customer-centric approach to development, and flawless platform interoperability. The company recently introduced enhanced incident response capabilities, improved event reporting, and expanded case management functionality, delivering deeper insights and faster decision-making capabilities. Furthermore, its alliance with International SOS to jointly develop enhanced travel risk management and workforce event management solutions further solidify Ontic’s role as a market leader.

“With such a customer-centric approach underpinning its growth strategy, Ontic’s continued industry leadership remains impressive in the face of high organic growth within the digital intelligence solutions market and an array of new vendors,” noted VanZandt.

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

“We’re honored to receive Frost & Sullivan’s 2025 Best Practices Company of the Year award recognizing Ontic’s commitment to innovation, excellence, and client success,” said Manish Mehta, Chief Product Officer, Ontic. “Our vision is to provide the system of record that security teams worldwide need to break down silos, modernize their operations, and prove their value as a strategic imperative to their organizations.”

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Camila Tinajero
Marketing & Events Coordinator – Best Practices Recognition
camila.tinajero@frost.com

About Ontic

Ontic makes software that corporate and government security professionals use to proactively manage threats, mitigate risks, and make businesses stronger. Built by security and software professionals, the Ontic Platform connects and unifies critical data, business processes, and collaborators in one place, consolidating security intelligence and operations. Ontic serves corporate security teams across key programs, including physical safety and security, executive protection, intelligence, investigations, incident management, and GSOC.

For more information, please visit ontic.co or follow us on X or LinkedIn.

Media contact:
Kat Brooks
Senior Manager, Corporate Communications
kbrooks@ontic.co

Porton Advanced’s End-to-End CDMO Solutions Accelerates IND Approval of Tasly’s Innovative Dual-Targeting CAR-T Therapy

SUZHOU, China, April 16, 2025 /PRNewswire/ — April 12, 2025, Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, “P134 Cell Injection,” which has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).

As the exclusive CDMO partner for this program, Porton Advanced provided comprehensive process development and manufacturing services, including plasmid, lentiviral vectors and final CAR-T cell products. We successfully manufactured dozens of batches of clinical-grade investigational products for Investigator-Initiated Trials (IITs), with all batches passing quality control on the first attempt.

About GMB and Tasly’s Dual-Targeting CAR-T Therapy

Glioblastoma (GBM) is the most common primary malignant tumor of the central nervous system, characterized by high invasiveness, frequent recurrence, and poor prognosis. P134 Cell Injection is an autologous CAR-T product targeting CD44 and/or CD133. Its mechanism of action involves specifically recognizing and binding to antigen targets that are highly and mutually exclusively expressed in primary and recurrent GBM, thereby effectively activating and prolonging T-cell lifespan to eliminate tumor cells.


Porton Advanced: Accelerating Progress of Advanced Therapies

Our team’s expertise in cell therapy development and cGMP production ensured high-quality, on-time delivery, contributing to Tasly’s continued effort in bringing innovative oncology treatments to patients worldwide. Notably, the regulatory submission achieved zero deficiencies during the CDE review, demonstrating the high compliance of our quality system and production stability.

  • Plasmid Production: A robust two-step chromatography process enabled rapid delivery of engineering run and GMP batches, significantly shortening timelines and reducing costs.
  • Lentivirus Production: Utilizing our proprietary LV-SMART® lentiviral suspension platform, we achieved high batch-to batch consistency, high yield, high infectious, low residual impurities as well as 30% reduced material cost with animal components free.
  • CAR-T Production: Porton Advanced produced high-transfection-efficiency CAR-T cells meeting with all release standards, delivered over 10 IIT samples with consistent quality, which contributes to observable clinical efficacy in IIT study.

Leveraging our end-to-end CDMO platform, Porton Advanced has established a deep collaboration with Tasly. We sincerely wish Tasly success in the clinical development of CAR-T pipeline and hope it will soon bring new treatment options to patients with recurrent glioblastoma. We look forward to further strengthening our partnership to accelerate the delivery of transformative therapies to patients worldwide.

About Tasly Pharma

As an international modern Chinese medicine enterprise, Tasly Pharma. (Stock code: 600535) is committed to developing into a leading solution provider of medicine and health services with global influence in China. With “people-oriented and precise innovation”, Tasly Pharma. constantly promotes the progress of medicine and health to make every human-being can enjoy the beauty and hope of life.

Headquartered in Tianjin, China, the company has more than 20 research centers worldwide and 11 production bases throughout the country. We are committed to cracking the digital code of life medicine. Adhering to the concept of “patient-centered”, we pay close attention to the evolution of disease spectrum, and make precise innovations in major therapeutic fields such as cardio-cerebrovascular, digestion and metabolism, tumor immunity, and neuroscience, which sustain the healthy life experience of human beings.

With a rich drug combination including modern Chinese medicine, chemical medicine and biological innovation medicine, regenerative medicine and the 4-D integrated health management solutions, we can provide service of the whole health journey including health examination, early warning, prevention, diagnosis, treatment and rehabilitation and a personalized and integrated medical solutions covering the whole disease course for each patient and family so as to meet the diverse needs of the individual life, optimize life experience and improve life quality.

About Porton Advanced

Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization.

Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV, etc), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc) and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector production lines, 12 GMP-compliant cell therapy production suites (including 2 suites for infectious donors), and a multitude of clean rooms. As of now, we have successfully supported our clients to secure 18 global IND approvals from NMPA, FDA, and Medsafe, with 5 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.

Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling effective drugs to benefit the public sooner.

NYSE Content Advisory: Pre-Market update + Nvidia quantifies tariff impact

NEW YORK, April 16, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-market update + Nvidia quantifies tariff impact

Kristen Scholer delivers the pre-market update on April 16th

  • Stocks are trading lower early Wednesday amid news from Nvidia regarding semiconductor trade
  • Shares fell 5% after the company said it will see a $5.5 Billion quarterly charge for exporting units to China and other countries
  • Investors anticipate the impact of the March retail sales report that saw economists estimate a raise of 1.2% from February’s initial read

Opening Bell
GallopNYC celebrates changing the lives of New Yorkers, one ride at a time

Closing Bell
Network for Teaching Entrepreneurship celebrates Financial Literacy Month by equipping the next generation with the skills to own their futures

Download the NYSE TV App and Subscribe Here 

 

Transforming Lives with TAVI: A Milestone in Aortic Stenosis Treatment

MANILA, Philippines, April 16, 2025 /PRNewswire/ — The Philippine Heart Center has reached a significant milestone by successfully performing six Transcatheter Aortic Valve Implantation (TAVI) procedures in a single day. This groundbreaking technique offers a minimally invasive alternative to open-heart surgery for patients with severe aortic stenosis, transforming lives and improving outcomes. The procedures were led by an expert heart team, including Dr. Ronaldo Estacio, Dr. Jhoanna Marcelo, and Dr. Kent Tan, who adhered to global standards to ensure safe and effective results.

PHC heart team celebrates 6 successful TAVI procedures in one day
PHC heart team celebrates 6 successful TAVI procedures in one day

Understanding Aortic Stenosis

Aortic stenosis is a serious heart valve condition characterized by narrowing and stiffening of the aortic valve, restricting blood flow from the heart to the body. This forces the heart to work harder, potentially leading to complications like heart failure. Symptoms include chest pain, shortness of breath, fatigue, and fainting, though some patients may remain asymptomatic until the disease progresses.

The Promise of TAVI

TAVI is a revolutionary procedure that replaces the damaged valve without removing it. A catheter is inserted through an artery in the groin or chest to deliver a new valve that expands and begins functioning immediately.

Benefits of TAVI:

  • Minimally invasive: Avoids large incisions or sternotomy.
  • Faster recovery: Patients typically return home within days.
  • Improved quality of life: Symptoms improve rapidly post-procedure.

Commitment to Excellence

The team at the Philippine Heart Center followed rigorous international protocols for patient selection, procedural planning, and safety measures. Their adherence to global standards ensured optimal outcomes while minimizing risks such as paravalvular leaks or vascular complications. Advanced imaging techniques and newer-generation devices contributed to the success of these procedures.

Compassionate Care

Recognizing the financial barriers many patients face, the Philippine Heart Center extended support to those unable to afford this life-saving treatment. This initiative ensures that cutting-edge therapies like TAVI are accessible to all, regardless of economic status.

Raising Awareness

Aortic stenosis can be managed effectively with timely intervention. Innovations like TAVI provide safer alternatives for high-risk patients who may not be candidates for traditional surgery. By increasing awareness about symptoms and treatment options, early diagnosis can save lives.

The Philippine Heart Center’s achievements set a benchmark for heart health in the region, combining medical innovation with compassionate care to transform lives.

TAVI treats aortic stenosis with a less invasive approach—no open-heart surgery
TAVI treats aortic stenosis with a less invasive approach—no open-heart surgery

 

 

Domestic Air Travel and Digital Wallet Trends Drive U.S. Mobile Driver’s License Install Base to 143 Million by 2030

NEW YORK, April 16, 2025 /PRNewswire/ — According to global intelligence firm ABI Research, the total install base for the U.S. mobile driver’s license (mDL) market is expected to reach 143 million by 2030, up from 21.73 million in 2025. This growth is being driven by three key factors: the REAL ID-compliant requirement for domestic air travel, third-party digital wallet providers like Apple and Google offering their mDLs for free to U.S. states, and the growing trend of U.S. states adopting the EU model by creating an all-encompassing government credential digital wallet.

“Although a small and steady number of states are choosing to roll their mDL into an all-in-one state credential digital wallet, most states are deploying an mDL-only approach to their digital licenses. The only real difference is if the mDL can be used as a full alternative to a physical license or only for domestic air travel,” explains Ash Robinson, Research Analyst at ABI Research.

ABI Research forecasts that by the end of 2030, 40 U.S. states will have implemented mobile driver’s licenses independently or through third-party digital wallet providers. The adoption of mDLs in the US typically progresses through three stages: First, mDLs are tested in pilot phases, often in small-scale trials such as in a large town or small city. Second, once deployed, mDLs are initially used primarily for domestic flights, allowing for widespread adoption while undergoing testing for any overlooked issues from the pilot phase. And third, mDLs are fully integrated as alternatives to physical licenses, accepted by law enforcement and for age verification purposes.

According to Robinson, “Mobile driver’s licenses in the US will see a large rise in usage in 2030 compared to use in the present day, but they will not totally replace their physical counterparts as U.S. mDLs are derived in nature with a physical license being needed to act as the primary documentation for mDL activation. Currently, 60% of the US driving population use a mDL.”

Over the next 10 years, U.S. mDL innovators and implementers need to focus efforts and strategies across two key areas: creating a standardized ruleset for mobile driver’s license regulation like the REAL ID scheme for physical licenses and, secondly, expanding use cases and functionality to achieve a multi-purpose singular government digital wallet.

These findings are from ABI Research’s U.S. Mobile Driver’s Licenses: Market Trends, Adoption Rates, and Challenges report. This report is part of the company’s Citizen Digital Identity Research service, which includes research, data, and ABI Insights.

About ABI Research

ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.

ABI Research是一家全球性的技术情报公司,拥有得天独厚的优势,充当终端市场公司和技术解决方案提供商之间的桥梁,通过提供独家研究和专业性指导,推动成功的技术实施和提供经证明可吸引和留住客户的战略,无缝连接这两大主体。

For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.

Contact Info

Global
Deborah Petrara
Tel: +1.516.624.2558
pr@abiresearch.com

 

IR Launches Capacity Management to Simplify Infrastructure Planning and Prevent Costly Outages

SYDNEY, April 16, 2025 /PRNewswire/ — Integrated Research (IR) (ASX:IRI), the world’s most trusted independent provider of observability for business-critical IT ecosystems, today unveiled a powerful new Capacity Management module with the launch of Prognosis 13.1.

By integrating infrastructure performance data with business forecasts, IR’s new Capacity Management module enables businesses to model multiple capacity scenarios, predict future needs, anticipate and prevent performance issues and optimize infrastructure investments.

Capacity Management is part of an ongoing innovation-led program of new products and capabilities, enabling clients to move beyond reporting and into meaningful discovery.

The technology infrastructure of large-scale payment platforms is under strain, with global digital transaction volumes set to almost triple from 2020 to 2030[1].

Performance challenges can lead to critical downtime, which costs businesses over $400 billion annually in lost revenue[2]. This also introduces heightened reputational, customer retention and regulatory risk for banks and payment providers.

“With digital transactions surging, businesses can no longer afford inaccurate or incomplete capacity planning,” said Michael Tomkins, Chief Technology Officer at IR.

“Capacity Management transforms how organizations manage their IT infrastructure, giving our clients the insights to scale confidently, predict future needs, and optimize infrastructure investments with precision in increasingly demanding environments.”

IR’s Capacity Management module is available now as part of the Prognosis 13.1 release. For more information, visit the website.

About Integrated Research (IR)

Integrated Research (IR) is the world’s most trusted independent provider of observability solutions for critical IT infrastructure, payments and communications ecosystems.

IR’s Prognosis platform provides the visibility and insight organizations need to optimize performance of their business-critical technology, deliver exceptional user experiences and drive growth through innovation.

Discover better with IR.